Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...

New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...

Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

Long-term survival data from the GEMSTONE-302 study were presented at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. CStone is actively communicating with regulatory authorities ...

Ed Schuuring, Senior Clinical Scientist in Molecular Pathology and Professor of Molecular Oncology in the Department of ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

Abstract: 380 Title: mRNA vaccination enhances TCRtg T cell therapy efficacy in solid tumors Session type: Poster Presentation Date: November 9 Presenting Author: Dr. Johannes Lutz, Director ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...